Total Payments
$21,226
2024 Payments
$14,267
Companies
9
Transactions
49
Medicare Patients
561
Medicare Billing
$112,887

Payment Breakdown by Category

Other$12,750 (60.1%)
Travel$5,031 (23.7%)
Consulting$2,159 (10.2%)
Food & Beverage$1,286 (6.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for serving as faculty or as a speaker for a medical education program $9,075 2 42.8%
Travel and Lodging $5,031 24 23.7%
Consulting Fee $2,159 1 10.2%
Honoraria $2,025 1 9.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,650 1 7.8%
Food and Beverage $1,286 20 6.1%

Top Paying Companies

Company Total Records Latest Year
Exelixis Inc. $13,471 17 $0 (2024)
Coherus Biosciences Inc. $2,286 4 $0 (2024)
Eisai Inc. $2,159 1 $0 (2023)
Merck Sharp & Dohme LLC $1,438 10 $0 (2022)
AstraZeneca Pharmaceuticals LP $830.98 11 $0 (2020)
AstraZeneca UK Limited $735.09 1 $0 (2019)
BeiGene USA, Inc. $129.26 1 $0 (2023)
Janssen Biotech, Inc. $101.60 1 $0 (2024)
Regeneron Pharmaceuticals, Inc. $75.14 3 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $14,267 23 Exelixis Inc. ($11,821)
2023 $2,305 3 Eisai Inc. ($2,159)
2022 $9.50 1 Merck Sharp & Dohme LLC ($9.50)
2021 $1,650 1 Exelixis Inc. ($1,650)
2020 $1,594 11 Merck Sharp & Dohme Corporation ($1,429)
2019 $1,401 10 AstraZeneca UK Limited ($735.09)

All Payment Transactions

49 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
12/19/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $30.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
12/18/2024 Exelixis Inc. CABOMETYX (Drug) Compensation for serving as faculty or as a speaker for a medical education program Cash or cash equivalent $4,620.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
12/13/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $204.09 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
12/12/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $210.30 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/25/2024 Exelixis Inc. CABOMETYX (Drug) Compensation for serving as faculty or as a speaker for a medical education program Cash or cash equivalent $4,455.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/22/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $287.88 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/22/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $280.94 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/12/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $70.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/12/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $32.99 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/11/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $357.98 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/09/2024 Regeneron Pharmaceuticals, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $32.04 General
Category: ONCOLOGY
11/07/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $356.96 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
11/07/2024 Coherus Biosciences Inc. LOQTORZI (Biological) Food and Beverage In-kind items and services $70.70 General
Category: Oncology
11/07/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $70.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
10/18/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $303.97 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
10/11/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $296.95 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
10/11/2024 Exelixis Inc. CABOMETYX (Drug) Travel and Lodging In-kind items and services $70.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
10/04/2024 Regeneron Pharmaceuticals, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $26.44 General
Category: ONCOLOGY
08/02/2024 Janssen Biotech, Inc. RYBREVANT (Drug) Food and Beverage In-kind items and services $101.60 General
Category: Oncology
06/02/2024 Coherus Biosciences Inc. LOQTORZI (Biological) Honoraria Cash or cash equivalent $2,025.00 General
Category: Oncology
06/02/2024 Coherus Biosciences Inc. LOQTORZI (Biological) Food and Beverage Cash or cash equivalent $152.02 General
Category: Oncology
06/02/2024 Coherus Biosciences Inc. LOQTORZI (Biological) Travel and Lodging Cash or cash equivalent $37.96 General
Category: Oncology
06/01/2024 Exelixis Inc. CABOMETYX (Drug) Food and Beverage In-kind items and services $174.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
12/20/2023 Eisai Inc. Lenvima (Drug) Consulting Fee Cash or cash equivalent $2,158.75 General
Category: Oncology
09/21/2023 Regeneron Pharmaceuticals, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $16.66 General
Category: ONCOLOGY

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 3 155 296 $107,332 $27,421
2022 3 138 333 $124,102 $33,174
2021 3 94 231 $81,629 $22,896
2020 6 174 338 $116,437 $29,395
Total Patients
561
Total Services
1,198
Medicare Billing
$112,887
Procedure Codes
15

All Medicare Procedures & Services

15 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 67 144 $56,565 $15,092 26.7%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 58 122 $33,841 $8,356 24.7%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 30 30 $16,926 $3,974 23.5%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 52 162 $63,371 $18,091 28.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 47 132 $36,696 $9,705 26.4%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 39 39 $24,035 $5,378 22.4%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 35 100 $38,693 $11,361 29.4%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 37 109 $29,472 $8,325 28.2%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 22 22 $13,464 $3,210 23.8%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 31 92 $28,380 $7,695 27.1%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 32 115 $30,297 $7,264 24.0%
99205 New patient office or other outpatient visit, typically 60 minutes Facility 2020 32 32 $18,780 $4,320 23.0%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 26 44 $15,450 $3,816 24.7%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2020 22 22 $13,081 $3,553 27.2%
99239 Hospital discharge day management, more than 30 minutes Facility 2020 31 33 $10,449 $2,747 26.3%

About Siddharth Sheth, D.O., MPH

Siddharth Sheth, D.O., MPH is a Student in an Organized Health Care Education/Training Program healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2013. The National Provider Identifier (NPI) number assigned to this provider is 1982947008.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Siddharth Sheth, D.O., MPH has received a total of $21,226 in payments from pharmaceutical and medical device companies, with $14,267 received in 2024. These payments were reported across 49 transactions from 9 companies. The most common payment nature is "Compensation for serving as faculty or as a speaker for a medical education program" ($9,075).

As a Medicare-enrolled provider, Sheth has provided services to 561 Medicare beneficiaries, totaling 1,198 services with total Medicare billing of $112,887. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.

Practice Information

Products in Payments

  • CABOMETYX (Drug) $13,471
  • LOQTORZI (Biological) $2,286
  • Lenvima (Drug) $2,159
  • LENVIMA (Drug) $1,429
  • IMFINZI (Drug) $830.98
  • TAGRISSO (Drug) $735.09
  • BRUKINSA (Drug) $129.26
  • RYBREVANT (Drug) $101.60
  • LIBTAYO (Biological) $75.14

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Pittsburgh